Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Drug Safety and Availability

Drug Safety and Availability

                        Drug Alerts and Statements
          Information about Nitrosamine Impurities in Medications
          Medication Guides
          Drug Safety Communications


                        Food and Drug Administration Overdose Prevention Framework
          Drug Shortages
          FDA Drug Safety Podcasts
          Information by Drug Class
          Medication Errors Related to CDER-Regulated Drug Products
          Postmarket Drug Safety Information for Patients and Providers
          Risk Evaluation and Mitigation Strategies | REMS
          Safe Use Initiative
          Drug Recalls
          Drug Supply Chain Integrity
          Multistate outbreak of fungal meningitis and other infections Home
          Drugs
          Drug Safety and Availability
          FDA's ISTAND Pilot Program accepts submission of first artificial intelligence-based and digital health technology for neuroscienceDrug Safety and Availability FDA's ISTAND Pilot Program accepts submission of first artificial intelligence-based and digital health technology for neuroscience
  
  	
    Share
    Post
    Linkedin

    Email
    Print**[1/23/2024]** FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) recently accepted a new submission into the Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program. This submission is the first artificial intelligence-based and digital health technology-based project and the first project in neuroscience to be accepted into ISTAND.

“This marks a pioneering step for the ISTAND program as the first artificial intelligence-based, digital health technology project in neuroscience to be accepted into the pilot program,” said Peter Stein, M.D., director of CDER’s Office of New Drugs. “Our acceptance aligns with FDA's vision of optimizing drug development and evaluation, potentially expediting the availability of safe and effective treatments.”

Launched in 2020, ISTAND aims to support the development of novel drug development tools (DDTs) to be used in regulatory applications for new medical products. The program opens opportunities for DDTs that do not fit into established pathways for evaluation and application such as for biomarkers and clinical outcome assessments.

The accepted letter of intent (LOI) submission is for an automated depression and anxiety severity measurement tool utilizing multiple behavioral and physiological indices of depression in a machine learning (ML) model to derive clinician-reported outcomes for depression and anxiety based on the Hamilton Depression Rating Scale (HAM-D) and Hamilton Anxiety Rating Scale (HAM-A) scores. This LOI represents both a digital health technology (DHT) and artificial intelligence (AI)/ML, both important areas of focus for FDA.

The LOI acceptance is the first step of the three-step qualification process in the DDT qualification programs, and it is based on several factors, including the scientific merit of the submission, the ability of the DDT to address a specified drug development need, the availability of information and resources that support the proposed qualification effort and demonstration that the DDT is feasible and practical within the proposed context of use. FDA will now work with the applicant to provide feedback on the next qualification step—a qualification plan.

FDA continues to foster innovative solutions in drug development, including AI/ML and DHTs, as outlined in recent publications to include “Using Artificial Intelligence & Machine Learning in the Development of Drug & Biological Products”, “Framework for the Use of Digital Health Technologies in Drug and Biological Product Development,” and the recent final guidance, “Digital Health Technologies for Remote Data Acquisition in Clinical Investigations.”

CDER and CBER are excited to advance the future of innovative DDT development with the first AI and DHT acceptance into the pilot program. We eagerly anticipate ISTAND’s role in advancing novel approaches to drug development and its contribution to bringing effective therapies to patients faster and more efficiently.

Find additional accepted ISTAND submissions in the CDER & CBER Drug Development Tool Qualification Project Search database.

For more information:

CDER Conversation: CDER Focuses on Novel Drug Development Tools to Help Speed Creation of New Therapies
	ISTAND Pilot Program Submission Process
	DDT Qualification Programs
	CDER & CBER Drug Development Tool Qualification Project Search
	Artificial Intelligence and Machine Learning (AI/ML) for Drug Development
	Digital Health Technologies (DHTs) for Drug Development
	CDER Statement: CDER and CBER accept first submission to ISTAND Pilot Program

                                                                                  Content current as of:
      01/23/2024
              
              
Regulated Product(s)
		 DrugsDrug Safety and Availability

          
                        Drug Alerts and Statements
          Information about Nitrosamine Impurities in Medications
          Medication Guides
          Drug Safety Communications


                        Food and Drug Administration Overdose Prevention Framework
          Drug Shortages
          FDA Drug Safety Podcasts
          Information by Drug Class
          Medication Errors Related to CDER-Regulated Drug Products
          Postmarket Drug Safety Information for Patients and Providers
          Risk Evaluation and Mitigation Strategies | REMS
          Safe Use Initiative
          Drug Recalls
          Drug Supply Chain Integrity
          Multistate outbreak of fungal meningitis and other infections
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop